Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Hyperplasia

Hyperplasia

48

Pipeline Programs↗

64

Active Trials↗

47

Companies Involved↗

Hyperplasia is a moderately active landscape with 48 programs across 47 companies. 12 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

58/100

Mech. Concentration

17/100

Completion Rate

85/100

Attrition Rate

10/100

Pipeline

Programs by Phase

Preclinical24

Medroxyprogesterone Acetate

Eli Lilly

Chlorhexidine Varnish

Khyber Medical University Peshawar

Sonazoid™

GE Healthcare

Isoflavones

National Center for Complementary and Integrative Health (NCCIH)

Alcohol

Astellas

Phase 13

Ad-116a

Addpharma Inc.

AD-1161

Addpharma Inc.

Alpha Receptor Antagonist

Yifeng Jing

Phase 29

Mounjaro

Eli Lilly

IV Busulfan

Otsuka

Mirena

Bayer

Everolimus

Novartis

Semaglutide

Novo Nordisk

Phase 312

Megestrol Acetate

Bristol-Myers Squibb

Lorazepam

Bausch Health Americas, Inc.

Letrozole

Novartis

Percocet Pill

University of Manitoba

Methoxyflurane - Penthrox

University of Manitoba

Approved

No programs

Analysis

Modality Breakdown

94%

Small molecule

44 of 47 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 47 classified programs, each share of the total. Modality classified for 98% of 48 pipeline programs.

Analysis

Trial Status

260

clinical trials

Completed152 · 58%

Recruiting27 · 10%

Not yet recruiting25 · 10%

Unknown status18 · 7%

Withdrawn13 · 5%

Terminated13 · 5%

Other12 · 5%

Clinical Trials

Trial Activity

260 trials

A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia

Recruiting·NNeurocrine Switzerland GmbH·Phase 2·NCT07536269·20 enrolled

Natural History Study of Patients With Excess Androgen

Recruiting·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00250159·3,000 enrolled

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension

Recruiting·CCrinetics Pharmaceuticals Inc.·Preclinical·NCT07159841·153 enrolled

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)

Recruiting·CCrinetics Pharmaceuticals Inc.·Phase 3·NCT07144163·150 enrolled

Evaluation of Potential Regret Related to Pediatric Surgical and Medical Management of Congenital Adrenal Hyperplasia, and Analysis of Long-term Outcomes.

Recruiting·UUniversity Hospital, Lille·N/A·NCT07781267·40 enrolled

Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes

Recruiting·NNorthwestern University·N/A·NCT05898932·300 enrolled

A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia

Recruiting·—·N/A·NCT05543200·7,500 enrolled

Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI/TRUS Fusion Imaging

Recruiting·Chinese PLA General Hospital·Preclinical·NCT06817733·30 enrolled

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06195306·66 enrolled

A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)

Recruiting·OOlympus Corporation of the Americas·Preclinical·NCT04757116·256 enrolled

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06184750·200 enrolled

Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study

Recruiting·UUrotronic Inc.·Preclinical·NCT06312722·92 enrolled

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer

Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05941520·80 enrolled

An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (CALM2-CAH)

Recruiting·CCrinetics Pharmaceuticals Inc.·Phase 2·NCT06712823·200 enrolled

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Recruiting·—·Phase 2/3·NCT05316493·172 enrolled

Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)